1. Amelioration of visual deficits and visual system pathology after mild TBI with the cannabinoid type-2 receptor inverse agonist SMM-189. (May 2019) Authors: Guley, Natalie M.; Del Mar, Nobel A.; Ragsdale, Tyler; Li, Chunyan; Perry, Aaron M.; Moore, Bob M.; Honig, Marcia G.; Reiner, Anton Journal: Experimental eye research Issue: Volume 182(2019) Page Start: 109 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Anti-inflammatory activity of cannabinoid receptor 2 ligands in primary hPDL fibroblasts. (March 2018) Authors: Abidi, Ammaar H.; Presley, Chaela S.; Dabbous, Mustafa; Tipton, David A.; Mustafa, Suni M.; Moore, Bob M. Journal: Archives of oral biology Issue: Volume 87(2018) Page Start: 79 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Cannabinoid type‐2 receptor agonist, inverse agonist, and anandamide regulation of inflammatory responses in IL‐1β stimulated primary human periodontal ligament fibroblasts. (20th June 2020) Authors: Abidi, Ammaar H.; Alghamdi, Sahar S.; Dabbous, Mustafa Kh.; Tipton, David A.; Mustafa, Suni M.; Moore, Bob M. Journal: Journal of periodontal research Issue: Volume 55:Number 5(2020) Page Start: 762 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Preclinical evaluation of SMM‐189, a cannabinoid receptor 2‐specific inverse agonist. Issue 4 (6th July 2015) Authors: Presley, Chaela; Abidi, Ammaar; Suryawanshi, Satyendra; Mustafa, Suni; Meibohm, Bernd; Moore, Bob M. Journal: Pharmacology research & perspectives Issue: Volume 3:Issue 4(2015:Aug.) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Preclinical evaluation of SMM‐189, a cannabinoid receptor 2‐specific inverse agonist. Issue 4 (6th July 2015) Authors: Presley, Chaela; Abidi, Ammaar; Suryawanshi, Satyendra; Mustafa, Suni; Meibohm, Bernd; Moore, Bob M. Journal: Pharmacology research & perspectives Issue: Volume 3:Issue 4(2015:Aug.) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Preclinical evaluation of SMM‐189, a cannabinoid receptor 2‐specific inverse agonist. Issue 4 (6th July 2015) Authors: Presley, Chaela; Abidi, Ammaar; Suryawanshi, Satyendra; Mustafa, Suni; Meibohm, Bernd; Moore, Bob M. Journal: Pharmacology research & perspectives Issue: Volume 3:Issue 4(2015:Aug.) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Raloxifene, a cannabinoid type-2 receptor inverse agonist, mitigates visual deficits and pathology and modulates microglia after ocular blast. (May 2022) Authors: Honig, Marcia G.; Del Mar, Nobel A.; Henderson, Desmond L.; O'Neal, Dylan; Yammanur, Meghna; Cox, Rachel; Li, Chunyan; Perry, Aaron M.; Moore, Bob M.; Reiner, Anton Journal: Experimental eye research Issue: Volume 218(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Synthesis and biological evaluation of (3′, 5′-dichloro-2, 6-dihydroxy-biphenyl-4-yl)-aryl/alkyl-methanone selective CB2 inverse agonist. Issue 17 (1st September 2015) Authors: Presley, Chaela S.; Mustafa, Suni M.; Abidi, Ammaar H.; Moore, Bob M. Journal: Bioorganic & medicinal chemistry Issue: Volume 23:Issue 17(2015) Page Start: 5390 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗